Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.39 |
| ▸ | KHK | P50053 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406276 | 0.92 | KHK (0.43) | EGLN2KHKTRPV4TSHRGAA | |
| SCHEMBL9821013 | 0.83 | EGLN2 (0.46) | EGLN2KHKTRPV4TSHRCYP11B1 | |
| SCHEMBL23730334 | 0.82 | TRPV4 (0.46) | EGLN2KHKTRPV4TSHRCYP11B1 | |
| SCHEMBL404483 | 0.82 | KHK (0.48) | EGLN2KHKTRPV4TSHRGAA | |
| SCHEMBL5287616 | 0.82 | TSHR (0.48) | EGLN2TSHRGAAKDM4ELMNA | |
| SCHEMBL862662 | 0.80 | TRPV4 (0.50) | EGLN2KHKTRPV4TSHRCYP11B1 | |
| SCHEMBL30583466 | 0.80 | TRPV4 (0.50) | EGLN2KHKTRPV4TSHRCYP11B1 | |
| SCHEMBL10257221 | 0.80 | TRPV4 (0.40) | EGLN2KHKTRPV4TSHRCYP11B1 | |
| SCHEMBL12225106 | 0.79 | KHK (0.39) | EGLN2KHKTRPV4GAACYP11B1 | |
| SCHEMBL16320147 | 0.77 | TSHR (0.37) | EGLN2TSHRKDM4EADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023125792-A1 | MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 杭州奥默医药股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20230172932-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-08 | — | — | US | disclosed |
| EP-2064180-B1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | MERCK SHARP & DOHME (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8901139-B2 | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8557848-B2 | 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8546420-B2 | 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8404845-B2 | 2,3-substituted azaindole derivatives for treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8268803-B2 | 5, 6-ring annulated indole derivatives and use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2197842-B1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORP (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20100322901-A1 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION | 2010-12-23 | — | — | US | disclosed |
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
| WO-2009152200-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009032123-A2 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | IDO1, IDO2, ZC3HAV1 | EGLN2 1159/4885KHK 3334/4885TRPV4 2021/4885 |
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | EGLN2 3374/4885KHK 1894/4885TRPV4 2651/4885 |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | EGLN2 297/4885KHK 2820/4885TRPV4 2318/4885 |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | EGLN2 162/4885KHK 3244/4885TRPV4 4232/4885 |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | EGLN2 3018/4885KHK 1851/4885TRPV4 2493/4885 |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | EGLN2 949/4885KHK 2522/4885TRPV4 2141/4885 |
| US-20230172932-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | TXN, TXNL1, TXN2 | EGLN2 1305/4885KHK 1253/4885TRPV4 4144/4885 |
| US-20100322901-A1 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF | IDO1, IDO2, TPH1 | EGLN2 1191/4885KHK 3288/4885TRPV4 4061/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | EGLN2 953/4885KHK 2747/4885TRPV4 421/4885 |
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | TXN, TXNL1, TXN2 | EGLN2 1305/4885KHK 1253/4885TRPV4 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.